Therefore, an antagonist gel that inhibits both CLR/RAMP1 and 2 may be useful for blocking CGRP- and ADM-mediated tumor growth and metastasis in patients (Vazquez et al., 2020). The gene discussed is DCLK3; the disease is neoplasm.